Positive FDA discussion lifts Rocket amid $175 million funding round

14 September 2023

Stock in New Jersey, USA-based Rocket Pharmaceuticals (Nasdaq: RCKT) shot up around 40% on Wednesday, following good news on the financing and regulatory fronts.

Rocket is working on genetic therapies for rare childhood disorders with high unmet need, following a platform-agnostic approach to target different indications.

The company announced on Tuesday that “alignment has been reached” with the US regulator on a pivotal Phase II trial for its lead candidate RP-A501, in the fatal genetic disorder Danon disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK